These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1398252)

  • 1. [Current developments in hormonal contraception].
    Kuhl H
    Gynakologe; 1992 Aug; 25(4):231-40. PubMed ID: 1398252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for prescribing oral contraceptives].
    Teichmann AT
    Wien Med Wochenschr; 1998; 148(7):171-4. PubMed ID: 9700865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral contraception: disadvantages of estrogen reduction].
    Denis C
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comparative clinical study of the effects of three types of low-dose estrogen/progestogen oral contraceptives].
    Chen JK
    Shengzhi Yu Biyun; 1987 May; 7(2):11-6. PubMed ID: 12268918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pros and cons of triphasic oral contraception].
    Berdah J
    Contracept Fertil Sex (Paris); 1985 Dec; 13(12):1205-10. PubMed ID: 12267512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three triphasic oral contraceptives now available in U.S.
    Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of biphasic and triphasic pills.
    Cohen J
    IPPF Med Bull; 1985 Aug; 19(4):1-2. PubMed ID: 12280230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene].
    Belaisch J; Hommais-loufrani B
    Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metrorrhagia caused by estrogen-progestin combinations].
    Erny R; Erny N
    Contracept Fertil Sex (Paris); 1994 Feb; 22(2):93-7. PubMed ID: 12319056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral contraception: advantages of estrogen reduction].
    Cohen J
    Contracept Fertil Sex (Paris); 1993 Jun; 21(6):489-94. PubMed ID: 12318239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current perspectives on combination oral contraceptives.
    Smith MA; Youngkin EQ
    Clin Pharm; 1984; 3(5):485-96. PubMed ID: 6386284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.